Mark Gallop

Mark Gallop is a biotechnology professional with over 30 years of experience in the industry. In 1989, they began their career as the Senior Director of Combinatorial Chemistry at Affymax Research Institute. In 1999, they co-founded XenoPort, Inc. and served as Senior Vice President of Research. From 2012-2018, they were the Chief Scientific Officer of Nurix Inc. and in 2018 they became the Executive-in-Residence at 5AM Venture Partners, LLC. In 2020, they joined BlueLight Therapeutics, Inc. as Chief Scientific Officer and Director. Most recently, they became the President of Light Horse Therapeutics in 2022.

Mark Gallop completed a Postdoc at the University of California, Berkeley from 1988-1989 in the field of Bioorganic Chemistry. Prior to that, they completed a Ph.D at the University of Cambridge from 1984-1987 in Inorganic Chemistry. Mark also completed an MSc at The University of Auckland from 1980-1984 in Chemistry.